Clifford Chance

Clifford Chance advises Silom Medical Company on sale to Actavis

International law firm Clifford Chance has advised the owners of Silom Medical Company, Thailand's largest pharmaceutical company, on its sale to Actavis plc, a leading global specialty pharmaceutical company, for approximately US$100 million in cash. The acquisition propels Actavis into a top position in the Thai generic pharmaceutical market, with leading positions in the ophthalmic and respiratory therapeutic categories and a strong cardiovascular franchise.

Silom Medical is one of Thailand's leading generic pharmaceutical companies, offering more than 25 products in various dosage forms to more than 4,400 hospitals, clinics and drugstores throughout the country. The Company has an experienced, in-house sales force and operates a sophisticated new 32,000 sq. meter manufacturing facility in Ayutthaya with a production capacity of 660 million tablets/capsules and 47 million sterile units per year.

Actavis is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter pharmaceutical products, and has commercial operations in approximately 60 countries.

"We are pleased to assist Silom Medical's owners with its sale to Actavis, as we share their pleasure in seeing Silom Medical, its staff and other stakeholders well placed for the future," commented Corporate partner Andrew Matthews. "With a rise in wealth driving interest in improved healthcare, we continue to see rapid growth of the pharmaceuticals industry in South East Asia."

The Clifford Chance team comprised Corporate partner Andrew Matthews, counsel Angela Nobthai, senior associate Sahachai Wibuloutai and associate Sirimas Porasupattana.